Randomized blinded study comparing injection site pain from octreotide long-acting-release (LAR) versus lanreotide during the treatment of well differentiated neuroendocrine tumors (WDNETs)

MLA

Tiffany Le, et al. “Randomized Blinded Study Comparing Injection Site Pain from Octreotide Long-Acting-Release (LAR) versus Lanreotide during the Treatment of Well Differentiated Neuroendocrine Tumors (WDNETs).” Journal of Clinical Oncology, vol. 39, May 2021, p. e16204. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........81117e0b948f8b6fdeb57cdf6c4b8525&authtype=sso&custid=ns315887.

APA

Tiffany Le, Diane Lauren Reidy, Olivia Heffernan, Leonard B. Saltz, Elizabeth Cruz, Marinela Capanu, Nitya Raj, Joanne F. Chou, & Haley Hauser. (2021). Randomized blinded study comparing injection site pain from octreotide long-acting-release (LAR) versus lanreotide during the treatment of well differentiated neuroendocrine tumors (WDNETs). Journal of Clinical Oncology, 39, e16204.

Chicago

Tiffany Le, Diane Lauren Reidy, Olivia Heffernan, Leonard B. Saltz, Elizabeth Cruz, Marinela Capanu, Nitya Raj, Joanne F. Chou, and Haley Hauser. 2021. “Randomized Blinded Study Comparing Injection Site Pain from Octreotide Long-Acting-Release (LAR) versus Lanreotide during the Treatment of Well Differentiated Neuroendocrine Tumors (WDNETs).” Journal of Clinical Oncology 39 (May): e16204. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........81117e0b948f8b6fdeb57cdf6c4b8525&authtype=sso&custid=ns315887.